- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab, BYL719 drink suspension
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 3,924
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain, Pancreatic Cancer
- Interventions
- morphine sulfate, Medtronic intrathecal pump
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib
- Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Brain Cancer, Pituitary Adenoma
- Interventions
- 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging, Blood and Urine samples
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
- Interventions
- CC-486, Vidaza
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
- Conditions
- Refractory or Relapsed Solid Tumors, Lymphoma
- Interventions
- Avelumab
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • The Bronx, New York
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- ziv-aflibercept, pharmacological study, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more
- Conditions
- Glioblastoma Multiforme, High-Grade Glioma
- Interventions
- Gliadel wafer, Temozolomide, External Beam Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Methodist Healthcare - Memphis
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Interventions
- Mitoxantrone
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Adult Brain Tumor, Lung Cancer, Radiation Toxicity
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-melanoma Skin Cancer
- Interventions
- Acetaminophen
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma, Spinal Cord Compression
- Interventions
- Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Radiation · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Brain Tumors
- Interventions
- Massage Therapy
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer, Colorectal Cancer, Pain
- Interventions
- Capecitabine, Celecoxib, Radiation Therapy, Placebo
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 13
- States / cities
- Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
- Conditions
- Lung Cancer
- Interventions
- CPAP
- Device
- Lead sponsor
- Mark M. Fuster, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Neurofibroma, Plexiform
- Interventions
- Imatinib Mesylate
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 6 Months to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Shoulder Pain, Head and Neck Cancer
- Interventions
- Questionnaires
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Sturge-Weber Syndrome
- Interventions
- Not listed
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2027
- U.S. locations
- 7
- States / cities
- Baltimore, Maryland • Detroit, Michigan • New York, New York + 4 more
- Conditions
- Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
- Interventions
- Armodafinil, placebo
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Childhood CNS Tumor
- Interventions
- SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
- Genetic · Radiation · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Brain Metastases
- Interventions
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, CD70 IHC assay
- Biological · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2044
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic Brainstem Glioma, Diffuse Intrinsic Pontine Glioma, DIPG Brain Tumor, H3 K27M
- Interventions
- SIACI of cetuximab and bevacizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida